Skip to main content

Table 5 Risk Factors for VTE among PsA Patients excluding cases with previous VTE

From: The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study

   

(Univariate Analysis)

Multivariate analysis

PsA+VTE

P value

HR

95% CI

P value

HR

95% CI

Age (Mean± SD, Median)

 

65.4±12.6

<0.0001

1.08

1.06-1.11

<0.0001

1.09

1.06-1.12

sex

Female

35/2785 (1.3%)

0.10

1.58

0.91-2.74

0.42

1.27

0.71-2.27

Male

20/2451 (0.8%)

 

Ref.

    

Socio-economic statusa

1-low

16/1607 (1.0%)

 

Ref.

 

0.42

0.76

0.40-1.47

2-medium

22/2028 (1.1%)

0.91

1.04

0.55-1.98

0.56

0.81

0.39-1.66

3-high

15/1317 (1.1%)

0.81

1.09

0.54-2.20

   

BMIa

BMI<25

13/1478 (0.9%)

 

Ref.

    

BMI≧25<30

18/1781 (1.0%)

0.91

1.04

0.51-2.13

0.49

0.78

0.38-1.60

BMI≧30

23/1742 (1.3%)

0.28

1.45

0.74-2.86

0.99

0.99

0.47-2.11

Tobacco use

Yes

21/2204 (1.0%)

0.60

0.87

0.50-1.49

0.89

0.96

0.54-1.69

No

34/3032 (1.1%)

 

Ref.

    

Psoriasis

Yes

45/4212 (1.1%)

0.72

0.88

0.44-1.75

0.54

0.80

0.39-1.63

No

10/1024 (1.0%)

 

Ref.

    

Comorbidity

Cancer

       

Yes

8/332 (2.4%)

0.003

3.07

1.45-6.50

0.19

1.68

0.77-3.65

No

47/4904 (1.0%)

 

Ref.

    

Diabetes

       

Yes

23/1753 (1.3%)

0.375

0.75

0.40-1.41

0.72

1.13

0.59-2.13

No

32/3483 (0.9%)

 

Ref.

    

IHD

       

Yes

11/535 (2.1%)

0.006

2.55

1.32-4.94

0.85

0.93

0.43-2.00

No

44/4701 (0.9%)

 

Ref.

    

CVA/TIA

       

Yes

6/237 (2.5%)

0.003

3.55

1. 52-8.31

0.21

1.79

0.72-4.46

No

49/4999 (1.0%)

 

Ref.

    

CHF

       

Yes

4/116 (3.4%)

<0.0001

7.22

2.58-20.2

0.03

3.84

1.16-12.6

No

51/5120 (1.0%)

 

Ref.

    

Hypertension

       

Yes

29/1565 (1.9%)

<0.0001

2.78

1.64-4.73

0.87

1.05

0.57-1.94

No

26/3671(0.7%)

 

Ref.

    

AF

       

Yes

2/153 (1.3%)

0.41

1.81

0.44-7.44

0.24

0.41

0.089-1.84

No

53/5083 (1.0%)

 

Ref.

    

Vascular disease

       

Yes

4/192 (2.1%)

0.064

2.62

    

No

51/5044 (1.0%)

 

Ref.

0.94-7.25

0.74

0.83

0.28-2.47

COPD

 

0.94

     

Yes

4/460 (0.9%)

 

0.96

0.35-2.67

0.51

0.71

0.25-1.99

No

51/4776 (1.1%)

 

Ref.

    

CRF

       

Yes

1/157 (0.6%)

1.00

1.00

0.14-7.27

0.20

0.26

0.032-2.02

No

54/5079 (1.1%)

 

Ref.

    

Medication

cDMARD

Yes 42/3681 (1.1%)

 

1.49

    

No 13/1555 (0.8%)

0.22

Ref.

0.79-2.82

0.18

1.58

0.81-3.10

bDMARD

Yes 19/1974 (1.0%)

0.94

1.02

0.57-1.85

0.15

1.58

0.85-2.92

No 36/3262 (1.1%)

 

Ref.

    
  1. aPresented data for percentages for socioeconomic status and BMI were calculated from the total number of the available data. Missing data for PsA+VTE group on socioeconomic status was 2/284 (0.70%) and 1/235 (0.43%), respectively.
  2. Abbreviations: AF Atrial fibrillation, c/b DMARD conventional/biologic disease-modifying anti-rheumatic drugs, BMI body mass index, CHF Congestive heart failure, COPD Chronic obstructive pulmonary disease, CRF Chronic renal failure, CVA Cerebrovascular accident, HR Hazard ratio, IHD Ischemic heart disease, PsA Psoriatic arthritis, Ref. Reference for calculation, SD Standard deviation, TIA Transient ischemic attack, VTE Venous thromboembolism.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us